NYSE:PBH • US74112D1019
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRESTIGE CONSUMER HEALTHCARE (PBH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-02 | Jefferies | Maintains | Hold -> Hold |
| 2025-11-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-27 | Jefferies | Maintains | Hold -> Hold |
| 2025-10-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-21 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-02-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-02-07 | DA Davidson | Maintains | Buy -> Buy |
| 2025-02-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-11 | DA Davidson | Maintains | Buy -> Buy |
| 2024-08-28 | DA Davidson | Maintains | Buy -> Buy |
| 2024-08-09 | DA Davidson | Maintains | Buy -> Buy |
| 2024-06-21 | DA Davidson | Upgrade | Neutral -> Buy |
| 2024-05-21 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-16 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-06-26 | DA Davidson | Reiterate | Neutral -> Neutral |
| 2023-05-08 | DA Davidson | Reiterate | Neutral |
| 2023-03-17 | RBC Capital | Maintains | Sector Perform |
| 2023-02-17 | Oppenheimer | Maintains | Outperform |
| 2023-01-13 | Oppenheimer | Maintains | Outperform |
| 2022-11-17 | Canaccord Genuity | Initiate | Buy |
| 2022-05-10 | Jefferies | Upgrade | Hold -> Buy |
| 2022-05-09 | DA Davidson | Maintains | Neutral |
| 2022-05-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-03-11 | BMO Capital | Maintains | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.128B 3.76% | 1.125B -0.21% | 1.138B 1.10% | 1.113B -2.18% | 1.136B 2.07% | 1.16B 2.11% | 1.164B 0.34% | 1.183B 1.63% | 1.181B -0.17% | |
| EBITDA YoY % growth | 385.527M 6.50% | 373.104M -3.22% | 379.414M 1.69% | 365.19M -3.75% | 377.13M 3.27% | 384.48M 1.95% | 389.42M 1.28% | 398.64M 2.37% | 397.94M -0.18% | |
| EBIT YoY % growth | 352.902M 6.97% | 342.429M -2.97% | 349.241M 1.99% | 335.8M -3.85% | 344.62M 2.63% | 353.84M 2.68% | 357.9M 1.15% | 367.21M 2.60% | 368.65M 0.39% | |
| Operating Margin | 31.29% | 30.43% | 30.70% | 30.17% | 30.34% | 30.50% | 30.75% | 31.04% | 31.22% | |
| EPS YoY % growth | -1.68 -141.38% | 4.17 348.21% | 4.53 8.63% | 4.59 1.25% | 4.85 5.65% | 5.08 4.80% | 5.29 4.12% | 5.59 5.64% | 5.53 -0.90% |
All data in USD
| Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.41 6.54% | 1.01 5.95% | 1.15 7.42% | 1.21 5.74% | 1.50 6.40% |
| Revenue Q2Q % growth | 299.49M 1.00% | 258.06M 3.42% | 282.48M 3.05% | 287.51M 1.44% | 314.41M 4.98% |
| EBITDA Q2Q % growth | 107.28M -18.15% | 82.045M 3.30% | 88.981M -6.33% | 94.031M -10.80% | 112.92M 5.26% |
| EBIT Q2Q % growth | 99.402M -1.48% | 75.475M 5.18% | 90.597M 13.72% | 98.677M 19.62% | 97.667M -1.75% |
All data in USD
10 analysts have analysed PBH and the average price target is 78.95 USD. This implies a price increase of 30.75% is expected in the next year compared to the current price of 60.38.
PRESTIGE CONSUMER HEALTHCARE (PBH) will report earnings on 2026-05-06, before the market open.
The consensus EPS estimate for the next earnings of PRESTIGE CONSUMER HEALTHCARE (PBH) is 1.41 USD and the consensus revenue estimate is 299.49M USD.
The consensus rating for PRESTIGE CONSUMER HEALTHCARE (PBH) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.